Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine
- PMID: 2015173
- PMCID: PMC1368414
- DOI: 10.1111/j.1365-2125.1991.tb03859.x
Metabolism of almitrine in extensive and poor metabolisers of debrisoquine/sparteine
Abstract
1. Almitrine bismesylate displays wide inter-subject variation in peak plasma concentrations and can induce peripheral polyneuropathy. 2. The phenotyped volunteer panel approach was used to examine whether almitrine oxidation displayed a genetic polymorphism of the debrisoquine/sparteine type. 3. There was no difference between poor and extensive metabolisers of debrisoquine with respect to the pharmacokinetics and metabolism of almitrine.
Similar articles
-
Genetic polymorphism of sparteine/debrisoquine oxidation: a reappraisal.Pharmacol Toxicol. 1990 Oct;67(4):273-83. doi: 10.1111/j.1600-0773.1990.tb00830.x. Pharmacol Toxicol. 1990. PMID: 2077517 Review.
-
The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions.J Med Genet. 1983 Oct;20(5):321-9. doi: 10.1136/jmg.20.5.321. J Med Genet. 1983. PMID: 6644761 Free PMC article.
-
Are poor metabolisers of sparteine/debrisoquine less pain tolerant than extensive metabolisers?Pain. 1993 Jun;53(3):335-339. doi: 10.1016/0304-3959(93)90229-I. Pain. 1993. PMID: 8351162
-
The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis.Eur J Clin Pharmacol. 1997;51(5):389-93. doi: 10.1007/s002280050219. Eur J Clin Pharmacol. 1997. PMID: 9049580
-
Polymorphic oxidation of debrisoquine and sparteine.Prog Clin Biol Res. 1986;214:157-67. Prog Clin Biol Res. 1986. PMID: 3523506 Review. No abstract available.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources